Table 1.
Baseline characteristics of patients according to their outcomes: critical evolution (ICU admission or death before 28 days after diagnosis) or non-critical evolution
| Characteristics | All patients (n = 122) | Non-critical evolution (n = 77) | Critical evolution (n = 45) | P-value |
|---|---|---|---|---|
| Age, median (IQR), years | 73.5 (64.2–81.2) | 73.0 (61.0–81.5) | 74.0 (66.6–84.0) | 0.07 |
| Female, n (%) | 43 (35) | 26 (34) | 17 (38) | 0.69 |
| BMI, median (IQR), kg/m2 | 25.3 (22.4–28.8) | 25.1 (22.4–28.6) | 26.5 (22.2–30.0) | 0.56 |
| ESRD vintage, median (IQR), years | 3.0 (1.0–5.5) | 2.7 (0.9–5.1) | 3.3 (1.4–7.2) | 0.23 |
| Haemodialysis, n (%)/peritoneal dialysis, n (%) | 119 (97.5)/3 (2.5) | |||
| Previous transplant, n (%) | 7 (6) | 7 (9) | 0 (0) | 0.05 |
| Location at COVID-19 diagnosis, n (%) | ||||
| At home | 82 (67) | 51 (66) | 31 (69) | 0.88 |
| In institution | 24 (20) | 15 (19) | 9 (20) | |
| Hospitalized | 16 (13) | 11 (14) | 5 (11) | |
| Champagne region | 67 (55) | 44 (66) | 23 (34) | 0.54 |
| Marseille | 55 (45) | 33 (60) | 22 (40) | |
| Cause of ESRD, n (%) | ||||
| Diabetes | 40 (33) | 22 (29) | 18 (40) | 0.03 |
| Hypertension | 31 (26) | 18 (23) | 13 (29) | |
| Glomerulonephritis | 19 (15) | 16 (21) | 3 (7) | |
| Genetic | 5 (4) | 1 (1) | 4 (9) | |
| Undetermined/other | 27(22) | 20 (26) | 7 (16) | |
| Comorbidities, n (%) | ||||
| Congestive heart failure (LVEF <45%) | 13 (11) | 5 (6) | 8 (18) | 0.07 |
| Ischaemic heart disease | 34 (28) | 18 (24) | 16 (36) | 0.21 |
| Atrial fibrillation | 41 (34) | 19 (25) | 22 (49) | 0.01 |
| Hypertension | 95 (78) | 62 (81) | 33 (73) | 0.37 |
| Diabetes | 64 (52) | 37 (48) | 27 (60) | 0.26 |
| Peripheral vascular disease | 34 (28) | 17 (22) | 17 (38) | 0.09 |
| Current smoker | 12 (10) | 6 (8) | 6 (13) | 0.36 |
| Chronic respiratory disease | 14 (11) | 9 (13) | 5 (11) | 0.99 |
| Cancer | 32 (26) | 21 (27) | 11 (24) | 0.83 |
| Obesity (BMI ≥30 kg/m²), n (%) | 25 (20) | 34 (35) | 11 (24) | 0.48 |
| Medication, n (%) | ||||
| ACEIs | 17 (14) | 10 (13) | 7 (16) | 0.78 |
| ARBs | 22 (18) | 18 (23) | 4 (9) | 0.05 |
| Antiplatelet agent | 65 (53) | 39 (51) | 26 (58) | 0.45 |
| Vitamin K antagonist | 26 (21) | 14 (18) | 12 (27) | 0.36 |
| Immunosuppressive therapy | 8 (7) | 6 (7) | 2 (4) | 0.71 |
Quantitative data are expressed in median (IQR 25–75% quartile).
LVEF, left ventricular ejection fraction.